Predictors of Seizure Outcome After Epilepsy Surgery in Pediatric Patients With Low-Grade Developmental and

Florian Mayer1, Matthias Tomschik2, Johannes Zielke1

  • 1Division of Neonatology, Intensive Care Medicine and Neuropediatrics, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Member of ERN EpiCARE, Vienna, Austria.

Pediatric Neurology
|July 18, 2025
PubMed

Insights

Complete tumor resection is crucial for seizure freedom in children with low-grade developmental and epilepsy-associated brain tumors (LEATs). However, early evaluation is vital as the seizure zone may extend beyond the tumor itself.

Area of Science:

  • Pediatric Neurology
  • Neurosurgery
  • Epileptology

Background:

  • Low-grade developmental and epilepsy-associated brain tumors (LEATs) frequently cause drug-resistant focal epilepsies in children.
  • While epilepsy surgery offers positive outcomes for many, 20-30% of patients remain seizure-free post-operation.

Purpose of the Study:

  • To identify predictors of postoperative outcomes and seizure recurrence in pediatric patients with LEATs.
  • To analyze factors influencing spontaneous or antiseizure medication (ASM) tapering-related seizure recurrence.

Main Methods:

  • Retrospective cohort study of pediatric patients with LEAT-associated epilepsy.
  • Analysis of clinical and demographic parameters impacting seizure recurrence after surgery.
  • Data collected from the Medical University of Vienna pediatric epilepsy center (1993-2023).

Main Results:

  • 74.4% of 82 patients achieved seizure freedom; 80% successfully discontinued ASMs.
  • Incomplete tumor resection was the strongest predictor of unfavorable outcomes (OR 53.5, P < 0.001).
  • Notably, 33% of patients with unfavorable outcomes had complete resections, often with longer epilepsy duration (84.1 vs 12.9 months, P=0.02).

Conclusions:

  • Complete tumor resection is essential for managing LEATs-associated epilepsy.
  • In cases of prolonged epilepsy, the epileptogenic zone may extend beyond the lesion, necessitating comprehensive preoperative evaluation.
  • Early and thorough preoperative assessment is critical for optimizing surgical outcomes and achieving seizure freedom.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
284
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
598
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
454